Cadrenal partners with Abbott for pivotal tecarfarin trial in LVAD patients

Cadrenal Therapeutics, Inc.

Cadrenal (CVKD) and Abbott (ABT) initiate collaborative effort for tecarfarin pivotal trial in recently implanted LVAD patients.
Tecarfarin received FDA Orphan Drug Designation in April 2024 for preventing clots in mechanical circulatory support devices.
Only LVAD available in U.S. is Abbott's HeartMate 3; collaboration aims to improve anticoagulation outcomes.
Prior clinical data suggest tecarfarin yields better anticoagulation quality in LVAD-relevant populations (multiple meds, renal impairment).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.